Throughout the last three months, 14 analysts have evaluated Apellis Pharmaceuticals (NASDAQ:APLS), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Insights from analysts’ 12-month price targets are revealed, presenting an average target of $76.5, a high estimate of $100.00, and a low estimate of $46.00. This current average has decreased by 3.65% from the previous average price target of $79.40. Decoding Analyst Ratings: A Detailed…